Biogena Group Invest AG (WBO:BIO) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 29, 2026)


WBO:BIO Biogena Group Invest AG WBO:BIO
66 GF Score
Price €4.20
GF Value €3.45
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biogena Group Invest AG Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Biogena Group Invest AG's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

WBO:BIO vs KHC, GIS, HRL: Margin of Safety % (DCF FCF Based) Comparison

For the Packaged Foods subindustry, Biogena Group Invest AG's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogena Group Invest AG Margin of Safety % (DCF FCF Based) vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Biogena Group Invest AG's Margin of Safety % (DCF FCF Based) falls into.


WBO:BIO
66GF Score
Biogena Group Invest AG WBO:BIO
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued. The current stock price of €4.20 is trading 21.7% above its estimated GF Value™ of €3.45. GuruFocus considers Biogena Group Invest AG to be Modestly Overvalued.

Key valuation signals for WBO:BIO:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €3.45 vs. price of €4.20 (21.7% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogena Group Invest AG Business Description

Address Strubergasse 24, Salzburg, AUT, 5020
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
66GF Score

Get the complete analysis for WBO:BIO

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.20
Price
€3.45
GF Value